SIRT6 Gene Therapy Innovations and Longevity Biotechnology
Genflow Biosciences Plc (LSE:GENF) has continued to advance its preclinical gene therapy pipeline engineered to halt or reverse the biological aging process and treat age-related degenerative diseases. Admitted to the Standard Segment of the Main Market of the London Stock Exchange, the UK-headquartered biopharmaceutical enterprise is the first European-listed pure-play longevity biotechnology company. Its therapeutic approach harnesses the biological mechanisms of SIRT6, a key longevity gene that regulates DNA repair, telomere maintenance, cellular metabolism, and systemic inflammation.
Lead Pipeline Indication: MASH and Liver Fibrosis
The primary clinical focus for Genflow is developing GF-1002, a specialized adeno-associated virus (AAV) vector carrying a centenarian variant of the human SIRT6 gene, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Preclinical in-vivo disease models have demonstrated that delivery of the SIRT6 centenarian gene significantly reduces hepatic fat accumulation, halts inflammatory cascade activation, and reverses established liver fibrosis, positioning GF-1002 as a potential disease-modifying genetic intervention for chronic liver degeneration.
Second Pipeline Indication: Werner Syndrome Progeria
In addition to chronic metabolic diseases, Genflow (LSE:GENF) is pursuing clinical development of GF-1004 targeting Werner Syndrome, a rare, fatal genetic progeria disorder characterised by premature, accelerated aging in young adults. Because patients with Werner Syndrome experience rapid tissue fibrosis, cardiovascular pathology, and premature mortality, securing Orphan Drug Designation from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provides an expedited clinical development and regulatory review pathway.
Capital Management and Non-Dilutive Funding
As a preclinical biotechnology company, Genflow (LSE:GENF) follows a Capital conservation approach. In its statutory financial disclosures, the company reported narrower operational cash outflows supported by non-dilutive funding grants from regional governments in Belgium and the European Union. The company does not currently pay a Dividend and maintains an unencumbered treasury position to fund animal toxicology studies and GMP batch manufacturing.
Upcoming Scientific Catalysts and IND Submission Milestones
Over the next twelve months, critical milestones for Genflow Biosciences (LSE:GENF) include concluding definitive preclinical safety studies for GF-1002, completing regulatory pre-IND interactions with the US FDA, and securing institutional clinical trial partnerships to commence first-in-human Phase 1/2 clinical studies in liver fibrosis.
Sector Context and Market Backdrop
Longevity biotechnology explores whether the biology of ageing can be influenced to treat age-related disease. SIRT6 is a gene associated with DNA repair and metabolic regulation, and variants found in people who live to a very old age have attracted scientific interest. Gene therapy approaches that deliver functional SIRT6 aim to address conditions such as liver fibrosis and progeroid syndromes, where there are few established treatments, and preclinical models are used to build the evidence needed before human trials.
What to Watch Next
Readers may follow animal toxicology results, GMP batch Manufacturing and preparation of regulatory submissions for the first clinical trials. Regional and European Union grants provide non-dilutive funding, so announcements of new awards would help to show external recognition of the programmes. The pipeline includes MASH and liver fibrosis as a lead indication, with Werner syndrome as a second, and scientific publications will add further context on how the platform is developing.






Please wait processing your request...